Research Uncovers Additional Potential Medicinal Benefits of Cannabis
In the past few years, cannabis has become a prominent talking point as more countries around the world give its citizens access to the plant. For instance, under international regulations cannabis is still considered a Schedule 1 Drug. In spite of this, however, several countries have already legalized the plant. Predominantly, most of these countries are legalizing cannabis for its medical benefits. However, several regions such as Canada and parts of the U.S. have legalized cannabis for recreational use as well. Nonetheless, the medical market currently accounts for the majority of the overall industry because of its global accessibility and availability. For instance, countries have legalized medical cannabis to treat chronic conditions such as severe pain, cancer, multiple sclerosis, and epilepsy. And while there are many other conditions that researchers believe cannabis can treat, due to the lack of large-scale clinical trials, regulators cannot approve the treatments. In response, researchers are constantly conducting innovative clinical trials to better understand the efficacy of cannabis and eventually intend to work towards implementing cannabis treatments into the medical marketplace. For example, Harvard University's Dana-Farber Cancer Institute recently released a study which suggested that cannabis can be an effective therapy for pancreatic cancer. To note, pancreatic cancer only accounts for 3% of all cancers in the U.S., but with a one-year survival rate of just 20%, it is projected to be the second leading cause of cancer deaths by 2020, according to the Pancreatic Cancer Action Network. The studies suggested that a chemical known as FBL-03G found within the cannabis plant can have "significant therapy potential." FBL-03G is a derivative of a cannabis flavonoid, which are also known to have anti-inflammatory benefits. The researchers concluded that by using the flavonoids as a tumor-targeted delivery therapy, it can possibly eradicate cancerous cells, increasing the rate of survivability. As more similar positive research continues to emerge, regulators could be more inclined to reevaluate the state of cannabis regulations. The global cannabis market is projected to grow from USD 10.3 Billion in 2018 to USD 39.4 Billion by 2023 at a CAGR of 30.7%, according to data compiled by MarketsandMarkets. Pasha Brands Ltd. (OTC: CRFTF) (CSE: CRFT), Innovative Industrial Properties, Inc. (NYSE: IIPR), HEXO Corp. (NYSE: HEXO) (TSX: HEXO), Valens GroWorks Corp. (OTC: VGWCF) (TSX-V: VGW), Harvest Health & Recreation, Inc. (OTC: HRVSF) (CSE: HARV)
CBD-Infused Drinks Tries to Offer a More Health Conscious Way to Consume Cannabis
As the cannabis industry continues to evolve, entrepreneurs are developing new and innovative products for consumers. Generally, most people stereotypically assume cannabis is consumed via smoking through rolled joints or other types of paraphernalia. However, as the legal cannabis market continues to expand, producers are introducing new offerings into the market. For instance, dried cannabis accounted for the majority of overall cannabis sales in legal regions. Several years later, many regions began to witness their dried cannabis sales fall as secondary products filled the gap. In particular, products such as concentrates, extracts, topicals, edibles, and beverages became widely popular among consumers. And beverages in particular have completely reshaped the way consumers can ingest cannabis. Unlike dried cannabis or concentrates, which require consumers to smoke or vape, beverages can be consumed without the adverse effects of smoking. Typically, most infused beverages are packed with CBD because of its widespread accessibility, as THC is still strictly regulated in almost every region across the world. And, generally, CBD beverages are being used by both consumers within the recreational and medical market because of its therapeutic benefits and calming properties. Recreational users may turn to infused beverages as relaxation stimulants, while medical users look to leverage them to treat a variety of conditions such as chronic pain, migraines, multiple sclerosis, schizophrenia, and epilepsy. With the growth in both the recreational and medical segments, the CBD infused beverage industry is positioned to become a leading market within the broad cannabis industry. And according to data compiled by Fior Markets, the global cannabis beverages market is expected to reach USD 4.56 Billion by 2025 while exhibiting a CAGR of 16.8% during the forecast period from 2018 to 2025. American Premium Water Corporation (OTC: HIPH), HEXO Corp. (NYSE: HEXO) (TSX: HEXO), New Age Beverages Corporation (NASDAQ: NBEV), The Alkaline Water Company Inc. (NASDAQ: WTER) (TSX-V: WTER), Emerald Health Therapeutics Inc. (OTC: EMHTF) (TSX-V: EMH)
This CBD Trend Holds a Significant Amount of Sales Potential
Demand for CBD-rich consumer products has been explosive since the U.S. Farm Bill was signed into law. In fact, the Brightfield Group estimates the U.S. CBD product market alone to be worth over $23.7 billion by 2023. Piper Jaffray says the potential for beauty products could boost the overall CBD market value to as much as $100 billion. Better, China is creating an explosive new trend, as it sees growing demand form skincare products tailored for men. In fact, in 2018, sales of male skincare products increased between 51% and 114% for cleansers, facial masks, lotions, and creams. If CBD finds its way into that mix, it could create a bigger catalyst for companies such as The Yield Growth Corp. (CSE:BOSS) (OTCQB:BOSQF), Canopy Growth Corporation (TSX:WEED)(NYSE:CGC), HEXO Corporation (NYSE:HEXO)(TSX:HEXO), OrganiGram Holdings Inc. (TSX-V:OGI) (NASDAQ:OGI), and Aphria Inc. (NYSE:APHA)(TSX:APHA).